These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22753584)

  • 41. Regulatory perspectives on multiplicity in adaptive design clinical trials throughout a drug development program.
    Wang SJ; Hung HM; O'Neill R
    J Biopharm Stat; 2011 Jul; 21(4):846-59. PubMed ID: 21516573
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials.
    Weng Y; Zhao W; Palesch Y
    Pharm Stat; 2012; 11(4):310-7. PubMed ID: 22589042
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overestimation of benefit when clinical trials stop early: a simulation study.
    Liu S; Garrison SR
    Trials; 2022 Sep; 23(1):747. PubMed ID: 36064448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statistical challenges in a regulatory review of cardiovascular and CNS clinical trials.
    Hung HM; Wang SJ; Yang P; Jin K; Lawrence J; Kordzakhia G; Massie T
    J Biopharm Stat; 2016; 26(1):37-43. PubMed ID: 26366624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A gated group sequential design for seamless Phase II/III trial with subpopulation selection.
    Miao G; Liao JJZ; Yang J; Anderson K
    BMC Med Res Methodol; 2023 Jan; 23(1):2. PubMed ID: 36597042
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Planned interim analysis and its role in cancer clinical trials.
    Geller NL
    J Clin Oncol; 1987 Sep; 5(9):1485-90. PubMed ID: 3625263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The shrinking or disappearing observed treatment effect.
    Chuang-Stein C; Kirby S
    Pharm Stat; 2014; 13(5):277-80. PubMed ID: 25182453
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing the impact of safety monitoring on the efficacy analysis in large Phase III group sequential trials with non-trivial safety event rate.
    Weng Y; Palesch YY; DeSantis SM; Zhao W
    J Biopharm Stat; 2016; 26(4):672-85. PubMed ID: 26010228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact that group sequential tests would have made on ECOG clinical trials.
    Rosner GL; Tsiatis AA
    Stat Med; 1989 Apr; 8(4):505-16. PubMed ID: 2657957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring in clinical trials: benefit or bias?
    Nardini C
    Theor Med Bioeth; 2013 Aug; 34(4):259-74. PubMed ID: 23824468
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Family-wise type I error rate control for an extended 2-in-1 design with graphical approach in oncology drug development.
    Li W; Zhou H; Jia C; Sun L
    Contemp Clin Trials; 2022 Aug; 119():106846. PubMed ID: 35803494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Multiple Endpoints in Oncology Clinical Trials].
    Hamasaki T; Bretz F
    Gan To Kagaku Ryoho; 2022 Apr; 49(4):371-380. PubMed ID: 35444117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Defining information fractions in group sequential clinical trials with multiple endpoints.
    Xu T; Qin Q; Wang X
    Contemp Clin Trials Commun; 2018 Jun; 10():77-79. PubMed ID: 29696161
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Two Stage Designs for Phase III Clinical Trials.
    Follmann D; Proschan M
    medRxiv; 2020 Jul; ():. PubMed ID: 32793927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Group sequential designs for in vivo studies: Minimizing animal numbers and handling uncertainty in power analysis.
    Blotwijk S; Hernot S; Barbé K
    Res Vet Sci; 2022 Jul; 145():248-254. PubMed ID: 35299085
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reply to S. Goteti et al.
    Freidlin B; Sun Z; Gray R; Korn EL
    J Clin Oncol; 2014 Mar; 32(8):856. PubMed ID: 24493728
    [No Abstract]   [Full Text] [Related]  

  • 57. Ebola treatments: trials stopped early for benefit tend to overestimate the effects of the intervention.
    Streiner DL
    BMJ; 2019 Oct; 367():l5789. PubMed ID: 31575523
    [No Abstract]   [Full Text] [Related]  

  • 58. Train-of-Four monitoring: overestimation.
    Han JU
    Korean J Anesthesiol; 2011 May; 60(5):311-2. PubMed ID: 21716959
    [No Abstract]   [Full Text] [Related]  

  • 59. Are we representing the true population in oncology trials?
    Lord SR; Hall PS; Seymour MT
    Ann Oncol; 2009 Dec; 20(12):2022. PubMed ID: 32560026
    [No Abstract]   [Full Text] [Related]  

  • 60. Improving Collection and Analysis of Overall Survival Data.
    Rodriguez LR; Gormley NJ; Lu R; Amatya AK; Demetri GD; Flaherty KT; Mesa RA; Pazdur R; Sekeres MA; Shan M; Snapinn S; Theoret MR; Umoja R; Vallejo J; Warren NJH; Xu Q; Anderson KC
    Clin Cancer Res; 2024 Sep; 30(18):3974-3982. PubMed ID: 39037364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.